Organisation paid for research Program year 2025 Source: CMS Open Payments

Clinical Trials Research Inc

Neither a doctor nor a teaching hospital

Research payments

$1,569,360

82 payments

Through program year 2025, Clinical Trials Research Inc is reported as receiving $1,569,360 in research payments, across 82 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $958,635 20
2024 Research $142,702 19
2023 Research $220,898 5
2022 Research $29,890 7
2021 Research $14,828 2
2020 Research $79,827 8
2019 Research $122,580 21

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,247,872 17 payments
  2. Sanofi US Services Inc. $189,699 28 payments
  3. Tolmar, Inc. $90,697 26 payments
  4. Mitsubishi Tanabe Pharma Development America, Inc. $17,887 1 payment
  5. Astellas Pharma Global Development $10,970 2 payments
  6. Pfizer Inc. $9,649 2 payments
  7. Esperion Therapeutics, Inc. $2,586 6 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $670,500 2 payments
  2. A Study of Remternetug Versus Placebo in Early Alzheimer's Disease Participants at Risk for Cognitive and Functional Decline $195,488 4 payments
  3. A Donanemab (Ly3002813) Prevention Study in Participants With Alzheimer's Disease (Trailblazer-Alz 3) $189,950 1 payment
  4. A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Effect of Efpeglenatide on Cardiovascular Outcomes in Type 2 Diabetes Patients at High Cardiovascular Risk $132,379 12 payments
  5. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $70,674 2 payments
  6. Tol-Clar-20024 $66,746 15 payments
  7. A Randomized, Open-Label, Parallel-Group, Two-Arm, Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes $64,732 5 payments
  8. A Randomized Open-Label Parallel-Group Two-Arm Phase 4 Study to Evaluate the Long-Term Efficacy and Safety of Tirzepatide Compared With Intensified Conventional Care in Adults When Initiating Treatment Early in the Course of Type 2 Diabetes $29,141 2 payments
  9. A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients With Type 2 Diabetes Who Have Inadequate Glyc $28,639 3 payments
  10. A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease $27,386 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record